Taste-masking can ensure success of a drug product, particularly those targeted to pediatric or geriatric populations.

Masking Taste: A Key Attribute to Success

FDA approval rate speeds up despite COVID-19 complications.

More than 50 New Drug Approvals in 2020

Biologics and complex compounds are mapping the course for drug delivery solutions.

Driving Drug Delivery Innovation

Equipment suppliers, CDMOs, and pharma collaborate to optimize manufacturing.

Who is Advancing Process Development?

Topic

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

In a pandemic, genetic vaccines offer several advantages over traditional approaches.

Genetic Vaccine Platforms Demonstrate Their Potential

Without an independent approval pathway for novel excipients, true pharmaceutical innovation could be stymied.

Novel Excipients Needed More Than Ever Before

Editor of Pharmaceutical Technology Europe

Various strategies to improve bioavailability are being continuously evaluated, affording greater commercial prospects for the future.

Reviewing Recent Bioavailability Research

FDA moves recommended timeline for API and drug manufacturers to assess impurity risks to March 31, 2021.

Nitrosamine Risk Assessment Date Extended

Through the acquisition, Catalent will establish pDNA development and manufacturing services at its Rockville, MD, facility and will gain Delphi’s team of R&D and genetic engineering scientists, technicians, and regulatory specialists.

Catalent to Acquire Delphi Genetics to Expand Plasmid DNA Capabilities 

Aprecia's compression-free 3DP manufacturing platform and Glatt’s multiparticulate technologies offer solutions to pharmaceutical dosage design challenges.

Glatt and Aprecia Collaborate on 3D-Printing for Solid-Dosage Drugs

The companies will co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications.

Eli Lilly to Collaborate with Rigel Pharmaceuticals for $960 Million 

With the acquisition, Eurofins gets Beacon’s G-protein coupled receptor research knowledge and its compound library. 

Eurofins to Expand Drug Discovery Capabilities Through Beacon Discovery Acquisition

The company has completed the expansion of its laboratory facilities to accommodate the development of APIs. 

Regis Technologies Completes Expansion of its Illinois Lab Facilities 

The companies have expanded their agreement to include the research and development of new therapies for influenza and other respiratory viruses.